Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Commentary|Videos|May 5, 2024
Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC
Author(s)Roger Li, MD
Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).
Advertisement
Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820) examining TAR-210 vs intravesical chemotherapy in patients with non–muscle-invasive bladder cancer.
Advertisement
Related to this article
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
3
INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
4
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer
5